5|10000|Public
40|$|The {{concentrative}} Na nucleoside transporter type 2 (CNT 2), cloned from a rat {{blood-brain barrier}} cDNA library, yields very high flux ratios for purine nucleosides after expression in frog oocytes. This high {{activity of the}} rat CNT 2 produced from the blood-brain barrier-derived cDNA, designated clone A- 11, en-abled a kinetic analysis of <b>2,</b> <b>3</b> <b>-dideoxyinosine</b> transport via the rat CNT 2. CNT 2 transported both adenosine and <b>2,</b> <b>3</b> <b>-dideoxyinosine.</b> The <b>2,</b> <b>3</b> <b>-dideoxyinosine</b> transport parameters included a Km of 29. 2 8. 3 M, a Vmax of 0. 40 0. 11 pmol/oocyte/min, and a constant of nonsaturable transport (KD) of 15. 7 0. 6 nl/oocyte/min. The <b>2,</b> <b>3</b> <b>-dideoxyinosine</b> Vmax was 27 -fold lower than the adenosine Vmax and the 2, 3 -dideoxyi-nosine KD was 15 -fold greater than the KD of adenosine transport. Adenosine inhibited both the saturable component o...|$|E
40|$|We {{previously}} reported that <b>2,</b> <b>3</b> <b>-dideoxyinosine</b> (didanosine, or ddI) significantly altered mitochondrial DNA (mtDNA) in {{peripheral blood mononuclear cells}} in {{human immunodeficiency virus}} type 1 (HIV- 1) -infected children who had undetectable plasma HIV- 1 RNA for more than 2 years while receiving highly active antiretroviral therapy. This research examines the in vitro effects of nucleoside reverse transcriptase inhibitors (NRTIs) on mitochondria of human skeletal muscle cells (HSMCs), including myoblasts and differentiated myotubes. mtDNA, mitochondrial RNA (mtRNA), and mRNA levels for nuclear mitochondrial regulatory factors were quantified in vitro using HSMCs, including myoblasts and differentiated myotubes, treated with NRTIs singly and in combination. After 5 days of treatment, mtDNA was significantly decreased in myoblasts and myotubes treated with ddI (P 0. 07). ddI and ddI-containing regimens significantly decrease mtDNA and mtRNA in HSMCs...|$|E
40|$|The use of {{nucleoside}} phosphorylases (NPs; EC 2. 4. 2. n) {{represents a}} convenient {{alternative to the}} chemical route for the synthesis of natural and modified nucleosides. We purified four recombinantly expressed nucleoside phosphorylases from the bacterial pathogens Citrobacter koseri, Clostridium perfringens, and Streptococcus pyogenes (CkPNPI, CkPNPII, CpUP, SpUP) and their substrate specificity was investigated towards either natural pyrimidine or purine nucleosides and some analogues, namely, arabinosyladenine (araA) and <b>2,</b> <b>3</b> <b>-dideoxyinosine</b> (ddI). A 23 % activity towards these latter compounds (compared to the natural substrates) was observed. Enzyme activities were compared to the specificities obtained for the enzymes pyrimidine nucleoside phosphorylase from Bacillus subtilis (BsPyNP) and purine nucleoside phosphorylase from Aeromonas hydrophila (AhPNPII) previously reported {{by some of the}} authors. The enzymes displaying the suitable specificity for the synthesis of araA and ddI were immobilized on aldehydeagarose. The immobilized preparations were highly stable at alkaline pH and in the presence of methanol or acetonitrile as cosolvent. They were used in the synthesis of araA and ddI by a one-pot, bienzymatic transglycosylation achieving 74 and 44 % conversion, respectively...|$|E
5000|$|... <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> 3,...|$|R
5000|$|... <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> 11, <b>2,</b> <b>3,</b> <b>2,</b> 7, <b>2,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> 5, <b>2,</b> 7, <b>2,</b> <b>3,</b> <b>2,</b> 5, <b>2,</b> 11, <b>2,</b> <b>3,</b> <b>2,</b> 19, <b>2,</b> 0, <b>2,</b> <b>3,</b> <b>2,</b> 7, <b>2,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> 11, <b>2,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> 5, <b>2,</b> 7, <b>2,</b> <b>3,</b> <b>2,</b> 5, <b>2,</b> 19, <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> 7, <b>2,</b> <b>3,</b> <b>2,</b> 19, <b>2,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> 13, <b>2,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> 5, <b>2,</b> 11, <b>2,</b> <b>3,</b> <b>2,</b> 5, <b>2,</b> 11, <b>2,</b> <b>3,</b> <b>2,</b> 7, <b>2,</b> 7, <b>2,</b> <b>3,</b> <b>2,</b> 0, ...|$|R
5000|$|... <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>2,</b> 2, 7, <b>2,</b> <b>2,</b> <b>3,</b> <b>2,</b> 17, <b>3,</b> <b>2,</b> <b>2,</b> 5, <b>3,</b> <b>2,</b> 5, 2, <b>2,</b> 229, <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> 5, <b>3,</b> <b>2,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> 7, <b>2,</b> <b>3,</b> 37, <b>2,</b> <b>3,</b> 5, 58543, <b>2,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>2,</b> 5, <b>3,</b> 4663, 54517, 17, <b>3,</b> <b>2,</b> 5, <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> 2, 47, 61, 19, ...|$|R
40|$|A novel {{series of}} 5 -O-ester prodrugs of the anti-HIV drug <b>2,</b> <b>3</b> <b>-dideoxyinosine</b> (ddI,didanosine) were {{synthesized}} {{for the purpose}} of increasing protein binding. Hope was that these derivates would exhibit superior pharmacodynamic and pharmacokinetic properties against HIV-infection than the parent drug, didanosine. Ten compounds were synthesized, five fatty acid derivates and five dicarboxylic acid monoester derivates. The fatty acid- and dicarboxylic acid derivates had the same carbon chain length. Chain lengths were 4, 6, 8, 12 and 16. The substances were tested for their protein binding ability in a 4 % bovine serum albumin (BSA) solution using ultrafiltration. Two of the derivates, 5 - dodecanedioic acid-(2, 3 -dideoxyinosine) -monoester (C 12) and 5 -hexadecanedioic-(2, 3 - dideoxyinosine) -monoester (C 16) showed high affinity for albumin. The two derivates demonstrated a protein binding of 95 % and 100 %, respectively. The parent compound, ddI, had a protein binding of < 5 % originally. The fatty acid and dicarboxylic acid derivate with a eight carbon chain were tried displaced with octanoic acid (C 8), oxazepam and warfarin. The displacement studies indicated that there are common binding sites for the C 8 derivates and the displacers...|$|E
40|$|Resistance {{to human}} {{immunodeficiency}} virus type 1 (HIV- 1) represents a significant problem {{in the design of}} novel therapeutics and the management of treatment regimens in infected persons. Resistance profiles can be elucidated by defining modifications to the viral genome conferred upon exposure to novel nucleoside reverse transcriptase (RT) inhibitors (NRTI). In vitro testing of HIV- 1 LAI-infected primary human lymphocytes treated with -D- 2, 3 -dideoxy- 2, 3 -didehydro- 5 -fluorocytidine (DFC; Dexelvucitabine; Reverset) produced a novel deletion of AGT at codon 68 (S 68) alone and in combination with K 65 R that differentially affects drug response. Dual-approach clone techniques utilizing TOPO cloning and pyrosequencing confirmed the novel S 68 in the HIV- 1 genome. The S 68 HIV- 1 RT was phenotyped against various antiviral agents in a heteropolymeric DNA polymerase assay and in human lymphocytes. Drug susceptibility results indicate that the S 68 displayed a 10 - to 30 -fold increase in resistance to DFC, lamivudine, emtricitabine, tenofovir, abacavir, and amdoxovir and modest resistance to stavudine, -D- 2, 3 -oxa- 5 -fluorocytidine, or 9 -(-D- 1, 3 -dioxolan- 4 -yl) guanine and remained susceptible to 3 -azido- 3 -deoxythymidine, <b>2,</b> <b>3</b> <b>-dideoxyinosine</b> (ddI), 1 -(-D-dioxolane) thymine (DOT) and lopinavir. Modeling revealed a central role for S 68 in affect-ing conformation of the 3 - 4 finger region and provides a rational for the selective resistance. These data indicate that the novel S 68 is a previously unrecognized deletion that may represent an important facto...|$|E
5000|$|... <b>2,</b> <b>2,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>2,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> <b>3,</b> <b>2,</b> 5, 2, 2, 2, <b>2,</b> 7, 5, <b>3,</b> <b>2,</b> <b>3,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>2,</b> 2, 5, 2, 2, 2, 7, 5, <b>2,</b> <b>3,</b> <b>2,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> 7, 7, <b>2,</b> <b>3,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> <b>3,</b> <b>2,</b> 2, 2, 11, 5, 2, 2, 5, <b>2,</b> <b>2,</b> <b>3,</b> 7, <b>3,</b> <b>2,</b> 2, ...|$|R
5000|$|... 0, <b>2,</b> 0, <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> 0, <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> 0, <b>2,</b> <b>3,</b> <b>2,</b> 7, <b>2,</b> 0, <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> 9, <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> 0, <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> 7, <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> 13, <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> 0, <b>2,</b> <b>3,</b> <b>2,</b> 15, <b>2,</b> 9, <b>2,</b> <b>3,</b> <b>2,</b> 7, <b>2,</b> 0, <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> 0, <b>2,</b> <b>3,</b> <b>2,</b> ...|$|R
5000|$|... <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> 11, <b>2,</b> <b>3,</b> 0, 7, <b>2,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> 5, <b>2,</b> 7, 0, <b>3,</b> <b>2,</b> 5, <b>2,</b> 11, <b>2,</b> <b>3,</b> <b>2,</b> 19, <b>2,</b> 0, <b>2,</b> <b>3,</b> <b>2,</b> 7, <b>2,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> 11, <b>2,</b> 5, 0, <b>3,</b> <b>2,</b> 5, <b>2,</b> 7, <b>2,</b> <b>3,</b> <b>2,</b> 5, <b>2,</b> 19, <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> 7, <b>2,</b> <b>3,</b> <b>2,</b> 19, <b>2,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> ...|$|R
5000|$|... 1, <b>2,</b> <b>2,</b> <b>3,</b> 3, 1, 1, 1, <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> 1, <b>2,</b> <b>3,</b> <b>3,</b> 1, 1, <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>3,</b> 1, <b>2,</b> <b>2,</b> <b>3,</b> 3, 3, 1, 1, 1, <b>2,</b> <b>3,</b> 1, 1, <b>2,</b> <b>2,</b> <b>3,</b> 3, 3, 1, 1, 1, <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> 1, 1, <b>2,</b> <b>2,</b> <b>3,</b> 3, 3, 1, 1, 1, <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> 1, <b>2,</b> <b>3,</b> 3, 1, 1, 1, <b>2,</b> <b>3,</b> 1, 1, <b>2,</b> <b>2,</b> <b>3,</b> 3, 3, 1, 1, 1, <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> 1, <b>2,</b> <b>3,</b> <b>3,</b> 1, 1, <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>3,</b> 1, <b>2,</b> <b>3,</b> 3,...|$|R
5000|$|... <b>2</b> 1 <b>3</b> <b>3</b> <b>2</b> 1 <b>3</b> <b>3</b> <b>2</b> 1 1 1 <b>3</b> 1 <b>2</b> <b>3</b> 1 3 3 1 1 3 3 1 1 1 <b>2</b> <b>3</b> <b>2</b> <b>3</b> 1 1 <b>2</b> <b>3</b> 1 1 <b>3</b> <b>2</b> 1 <b>2</b> <b>3</b> <b>3</b> 1 <b>2</b> <b>2</b> <b>3</b> <b>3</b> 1 1 <b>2</b> <b>3</b> <b>2</b> <b>2</b> <b>3</b> ...|$|R
5000|$|... 1, <b>2,</b> <b>2,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>2,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> 6, <b>3,</b> 5, <b>2,</b> 2, 2, <b>2,</b> 7, 5, <b>3,</b> <b>2,</b> <b>3,</b> 5, <b>2,</b> 5, <b>2,</b> 6, <b>3,</b> <b>3,</b> <b>2,</b> <b>3,</b> <b>2,</b> 2, 6, 5, 2, 5, 2, 2, 2, 19, 5, <b>2,</b> <b>3,</b> <b>2,</b> <b>3,</b> <b>2,</b> 6, <b>3,</b> 7, 7, 6, <b>3,</b> 5, <b>2,</b> 6, 5, <b>3,</b> <b>3,</b> <b>2,</b> 5, 17, 10, <b>2,</b> <b>3,</b> 10, <b>2,</b> <b>2,</b> <b>3,</b> 7, 6, <b>2,</b> 2, ...|$|R
5000|$|... 0, 1, 1, 2, 1, <b>2,</b> <b>2,</b> <b>3,</b> 1, <b>2,</b> <b>2,</b> <b>3,</b> <b>2,</b> <b>3,</b> <b>3,</b> 4, 1, <b>2,</b> <b>2,</b> <b>3,</b> <b>2,</b> <b>3,</b> <b>3,</b> 4, <b>2,</b> <b>3,</b> 3, 4, 3, 4, 4, 5, ...|$|R
5000|$|... <b>2,</b> <b>3,</b> <b>2,</b> <b>3,</b> <b>2,</b> 5, <b>3,</b> 0, <b>2,</b> 17, <b>2,</b> 5, <b>3,</b> <b>3,</b> <b>2,</b> <b>3,</b> <b>2,</b> 19, <b>3,</b> <b>3,</b> <b>2,</b> 5, <b>3,</b> 0, 7, <b>3,</b> <b>2,</b> 5, <b>2,</b> 7, 0, <b>3,</b> 13, 313, <b>2,</b> 13, <b>3,</b> 349, <b>2,</b> <b>3,</b> <b>2,</b> 5, 5, 19, 2, 127, 19, 0, <b>3,</b> 4229, <b>2,</b> 11, <b>3,</b> 17, 7, <b>3,</b> <b>2,</b> <b>3,</b> <b>2,</b> 7, <b>3,</b> 5, 0, 19, <b>2,</b> 19, 5, <b>3,</b> <b>2,</b> <b>3,</b> <b>2,</b> ...|$|R
5000|$|... <b>3,</b> <b>2,</b> <b>2,</b> 5, <b>2,</b> <b>3,</b> <b>2,</b> <b>3,</b> 5, 5, <b>2,</b> <b>3,</b> <b>2,</b> <b>3,</b> <b>3,</b> 7, <b>2,</b> 17, <b>2,</b> <b>3,</b> <b>3,</b> 11, <b>2,</b> <b>3,</b> 11, 0, <b>3,</b> 7, <b>2,</b> 109, <b>2,</b> 5, <b>3,</b> 11, 31, 5, <b>2,</b> <b>3,</b> 53, 17, <b>2,</b> 5, 2, 103, 7, 5, <b>2,</b> 7, 1153, <b>3,</b> 7, 21943, <b>2,</b> <b>3,</b> 37, 53, <b>3,</b> 17, <b>2,</b> 7, <b>2,</b> <b>3,</b> 0, 19, 7, <b>3,</b> <b>2,</b> 11, <b>3,</b> 5, <b>2,</b> ... (notice this OEIS {{sequence}} {{does not}} allow [...] ) ...|$|R
5000|$|... 4, 4, 3, 3, 3, 4, <b>3,</b> <b>3,</b> <b>2,</b> <b>3,</b> 3, 4, <b>3,</b> <b>3,</b> <b>2,</b> <b>3,</b> 3, 4, <b>3,</b> <b>3,</b> <b>2,</b> <b>3,</b> <b>3,</b> 4, <b>2,</b> <b>3,</b> <b>2,</b> <b>3,</b> 3, 4, ...|$|R
5000|$|... 2, <b>2,</b> 1, 1, <b>3,</b> 1, <b>3,</b> <b>3,</b> <b>3,</b> <b>2,</b> 1, 1, 1, 2, 2, 2, 1, 1, 1, <b>3,</b> <b>3,</b> <b>2,</b> 1, <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>3,</b> 1, 3, 1, 1, 1, 3, 3, 3, 1, 1, <b>3,</b> <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> 3, 1, 1, 3, 3, 3, 1, 1, 1, 3, <b>3,</b> 1, 1, <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> 1, 1, 1, <b>3,</b> 1, <b>3,</b> <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>3,</b> <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>3,</b> <b>2,</b> 2, 1, 1, <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>3,</b> <b>2,</b> 2, 2, 1, 2, 1, 1, 1,...|$|R
5000|$|... 0, 1, 1, 1, 1, 1, 1, 2, 1, 1, <b>2,</b> <b>3,</b> <b>2,</b> 1, 1, <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> <b>2,</b> 2, 2, 1, <b>2,</b> 4, <b>2,</b> <b>3,</b> <b>2,</b> 2, 2, <b>2,</b> 1, 1, <b>3,</b> 4, <b>2,</b> 4, 4, <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> 2, 4, 2, 4, 4, <b>2,</b> 5, <b>3,</b> 4, <b>3,</b> <b>2,</b> <b>3,</b> <b>3,</b> 4, <b>2,</b> <b>2,</b> <b>3,</b> 4, <b>2,</b> 4, 4, 4, <b>3,</b> <b>2,</b> <b>3,</b> 5, 4, <b>2,</b> 1, ...|$|R
40|$|Tubacin {{prevents}} neuronal migration {{defects and}} epileptic activity caused by rat Srpx 2 silencing in utero Manal Salmi, 1, <b>2,</b> <b>3,</b> 4, * Nadine Bruneau, 1, <b>2,</b> <b>3,</b> 4, * Jennifer Cillario, 1, <b>2,</b> <b>3,</b> 4, * Natalia Lozovaya, 1, <b>2,</b> <b>3,</b> 5 Annick Massacrier, 1, <b>2,</b> <b>3,</b> 4 Emmanuelle Buhler, 1, <b>2,</b> <b>3,</b> 4, 6 Robin Cloarec, 1, <b>2,</b> <b>3,</b> 4 Timur Tsintsadze, 1, <b>2,</b> <b>3,...</b>|$|R
5000|$|... 1, <b>2,</b> <b>2,</b> <b>3,</b> 3, 4, 4, 4, 1, 1, 1, 2, <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> 3, 3, 3, 4, 4, 4, 4, 1, <b>2,</b> <b>3,</b> 4, 4, 1, 1, <b>2,</b> <b>2,</b> <b>3,</b> 3, 4, 4, 4, 1, 1, 1, <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> 3, 3, 4, 4, 4, 4, 1, 1, 1, 1, 2, <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> 3, 3, 3, 4, 1, 1, <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> 3, 3, 3, 4, 4, 4, 4, 1, <b>2,</b> <b>3,</b> 3, 4, 4, 1, 1, 1, <b>2,</b> <b>2,</b> <b>2,</b> <b>3,</b> 3, 3, 3, 4, 4, 4, 4, 1, 1, 1, 1, <b>2,</b> <b>3,</b> 4, 1, 1,...|$|R
40|$|Contents 2. 1 Introduction 2. 2 Drug Distribution 2. 2. 1 Introduction to drug {{distribution}} 2. 2. 2 Protein binding <b>2.</b> <b>2.</b> <b>3</b> Factors that modify protein binding and {{drug distribution}}? 2. 2. 4 Blood brain barrier 2. 2. 5 Volume of distribution <b>2.</b> <b>3</b> Drug Metabolism <b>2.</b> <b>3.</b> 1 Introduction <b>2.</b> <b>3.</b> <b>2</b> Phase I <b>2.</b> <b>3.</b> <b>2.</b> 1 Induction <b>2.</b> <b>3.</b> <b>2.</b> <b>2</b> Inhibition <b>2.</b> <b>3.</b> 3 Phase II: Conjugation <b>2.</b> <b>3.</b> 4 First pass metabolism and bioavailability <b>2.</b> <b>3.</b> 5 Prodrugs <b>2.</b> <b>3.</b> 6 Pharmacologically active metabolites <b>2.</b> <b>3.</b> 7 Pharmacological toxic metabolites 2. 4 Drug Elimination 2. 4. 1 Introduction 2. 4. 2 Kidney 2. 4. 2. 1 Introduction 2. 4. 2. 2 Secretion and Reabsorption <b>2.</b> 4. <b>2.</b> <b>3</b> Renal insufficiency <b>2.</b> 4. <b>3</b> Other routes of excretion 2. 5 Blood levels 2. 5. 1 Elimination half-life 2. 5. 2 First and zero order kinetics <b>2.</b> 5. <b>3</b> Minimum effective and steady-state concentrations 2. 5. 4 Maintenance doses and loading dose...|$|R
5000|$|... 1, 1, <b>2,</b> 1, <b>2,</b> <b>3,</b> 1, <b>2,</b> <b>3,</b> 4, 1, <b>2,</b> <b>3,</b> 4, 5, 1, <b>2,</b> <b>3,</b> 4, 5, 6, ...|$|R
40|$|In {{this paper}} we first {{investigate}} for what positive integers a,b,c every nonnegative integer n {{can be represented}} as x(ax+ 1) +y(by+ 1) +z(cz+ 1) with x,y,z integers. We show that (a,b,c) can be either of the following seven triples: (1, <b>2,</b> <b>3),</b> (1, <b>2,</b> 4), (1, 2, 5), (2, 2, 4), (2, <b>2,</b> 5), (<b>2,</b> <b>3,</b> <b>3),</b> (<b>2,</b> <b>3,</b> 4), and conjecture that any triple (a,b,c) among (2, <b>2,</b> 6), (<b>2,</b> <b>3,</b> 5), (<b>2,</b> <b>3,</b> 7), (<b>2,</b> <b>3,</b> 8), (<b>2,</b> <b>3,</b> 9), (<b>2,</b> <b>3,</b> 10) also has the desired property. For integers 0 2, we prove that any nonnegative integer can be represented as x(ax+b) +y(ay+c) +z(az+d) with x,y,z integers, {{if and only if}} the quadruple (a,b,c,d) is among (<b>3,</b> 0, 1, <b>2),</b> (<b>3,</b> 1, 1, <b>2),</b> (<b>3,</b> 1, <b>2,</b> <b>2),</b> (<b>3,</b> 1, <b>2,</b> <b>3),</b> (4, 1, <b>2,</b> <b>3).</b> Comment: 9 pages, final published versio...|$|R
5000|$|Kotekan 1 <b>2</b> <b>3</b> 1 <b>2</b> <b>3</b> 1 <b>2</b> <b>3</b> 1 <b>2</b> <b>3</b> 1 <b>2</b> <b>3</b> 1 etc... Pokok 1 [...] [...] [...] 2 [...] [...] [...] 3 [...] [...] [...] 1 [...] [...] [...] etc...|$|R
5000|$|... 2, 15, 2, ?, <b>2,</b> 11, 10, <b>3,</b> <b>2,</b> ?, <b>2,</b> 5, ?, <b>3,</b> <b>2,</b> 13, <b>2,</b> ?, ?, <b>3,</b> <b>2,</b> ?, 9, 7, ?, ?, <b>2,</b> ?, <b>2,</b> 7, ?, <b>3,</b> 5, 25, <b>2,</b> 323, 226, <b>3,</b> <b>2,</b> ?, <b>2,</b> 5, ?, <b>3,</b> <b>2,</b> 31, 85, 7, ?, ?, <b>2,</b> ?, 14, 5, ?, <b>3,</b> <b>2,</b> ?, 2, ?, ?, 15, 10, ?, ...|$|R
25|$|For example, {{suppose the}} data values are 0, <b>3,</b> 4, 1, <b>2,</b> <b>3,</b> 0, <b>2,</b> 1, <b>3,</b> <b>2,</b> 0, <b>2,</b> <b>2,</b> <b>3,</b> <b>2,</b> 5, <b>2,</b> <b>3,</b> 999.|$|R
5000|$|... 2, 2, 1093, 11, 2, 2, 66161, 5, <b>2,</b> <b>2,</b> <b>3,</b> 71, <b>2,</b> 2, 29, 29131, <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> 2, 13, 13, <b>2,</b> <b>2,</b> <b>3,</b> <b>3,</b> <b>2,</b> 2, 7, 7, <b>2,</b> <b>2,</b> 46145917691, <b>3,</b> <b>2,</b> 2, 17, 8039, 2, 2, 23, 5, <b>2,</b> <b>2,</b> <b>3,</b> ...|$|R
5000|$|... (inSkill (apply 'plus '(1 <b>2</b> <b>3</b> 4 5 6 7)))(inScheme (apply plus '(1 <b>2</b> <b>3</b> 4 5 6 7)))(inSkill (apply 'plus 1 <b>2</b> <b>3</b> '(4 5 6 7)))(inScheme (apply plus 1 <b>2</b> <b>3</b> '(4 5 6 7)))(inSkill (funcall 'plus 1 <b>2</b> <b>3</b> 4 5 6 7)))(inScheme (funcall plus 1 <b>2</b> <b>3</b> 4 5 6 7))) ...|$|R
40|$|The {{behavioural}} and anticonvulsant {{effects of}} several 1 -aryl- 3, 5 -dihydro- 4 H- <b>2,</b> <b>3</b> -benzodiazepin- 4 -ones (<b>2,</b> <b>3</b> -BZs) and of 11 b-aryl- 7, 11 -dihydro- <b>3</b> -phenyl[1, <b>2,</b> 4]oxadiazolo[5, 4 -a][2, 3]benz odiazepin- 6 -ones (<b>2,</b> <b>3</b> -OBZs) were studied after intraperitoneal (i. p.) administration in DBA/ 2 mice, a strain genetically susceptible to sound-induced seizures. The seizures were evoked {{by means of}} auditory stimulation (109 dB, 12 - 16 kHz) in animals placed singly under a hemispheric Perspex dome. The <b>2,</b> <b>3</b> -benzodiazepines studied after 30 min pretreatment were generally less potent than the related derivative 1 -(4 -aminophenyl) - 4 -methyl- 7, 8 -methylenedioxy- 5 H- <b>2,</b> <b>3</b> -benzodiazepine hydrochloride (GYKI 52466) except 3, 5 -dihydro- 7, 8 -dimethoxy- 1 -phenyl- 4 H- <b>2,</b> <b>3</b> -benzodiazepin- 4 -one (<b>2,</b> <b>3</b> -BZ- <b>2)</b> and <b>2,</b> <b>3</b> -BZ- <b>2</b> M (<b>3</b> -methyl derivative of <b>2,</b> <b>3</b> -BZ- <b>2)</b> which showed comparable activity. Thirty minutes after i. p. administration of <b>2,</b> <b>3</b> -benzodiazepines, the rank order of potency for anticonvulsant activity against clonus was <b>2,</b> <b>3</b> -BZ- <b>2</b> > GYKI 52466 > <b>2,</b> <b>3</b> -BZ- <b>2</b> M > <b>2,</b> <b>3</b> -BZ- 1 > <b>2,</b> <b>3</b> -BZ- <b>3,</b> > <b>2,</b> <b>3</b> -OBZ- 1, > <b>2,</b> <b>3</b> -OBZ- <b>2</b> <b>2,</b> <b>3</b> -OBZ- 3. The intracerebroventricular (i. c. v.) injection of aniracetam on it own (12. 5 - 100 nmol/mouse) had no convulsant activity, but it reversed the anticonvulsant effects of some <b>2,</b> <b>3</b> -benzodiazepines. In particular, the pharmacological actions of GYKI 52466, <b>2,</b> <b>3</b> -BZ- <b>2</b> and <b>2,</b> <b>3</b> -BZ- <b>2</b> M, which {{proved to be the}} most potent <b>2,</b> <b>3</b> -benzodiazepine derivatives as anticonvulsants, were significantly reduced by an i. c. v. pretreatment with aniracetam (50 nmol/mouse). Concomitant treatment with aniracetam (50 nmol/mouse) shifted to the right the dose-response curves and significantly increased the ED 50 values for GYKI 52466, <b>2,</b> <b>3</b> -BZ- <b>2</b> and <b>2,</b> <b>3</b> -BZ- <b>2</b> M. After 30 min pretreatment <b>2,</b> <b>3</b> -BZ- <b>2</b> showed a similar potency to GYKI 52466 in antagonizing seizures induced by i. c. v. administration of alpha-amino- 3 -hydroxy- 5 -methyl- 4 -isoxazolepropionic acid (AMPA), thus suggesting a clear involvement of AMPA receptors in the anticonvulsant activity of these compounds. In addition, <b>2,</b> <b>3</b> -BZ- <b>2</b> and <b>2,</b> <b>3</b> -BZ- <b>2</b> M showed anticonvulsant properties longer lasting than GYKI 52466...|$|R
5000|$|In theory, {{the message}} is then {{converted}} to its coordinates in this grid; in practice, {{it is more convenient}} to write the triplets of trits out in a table, like so:Then the coordinates are written out vertically beneath the message: T R E A T Y E N D S B O E R W A R [...] <b>2</b> 1 <b>3</b> <b>3</b> <b>2</b> 1 <b>3</b> <b>3</b> <b>2</b> 1 1 1 <b>3</b> 1 <b>2</b> <b>3</b> 1 3 3 1 1 3 3 1 1 1 <b>2</b> <b>3</b> <b>2</b> <b>3</b> 1 1 <b>2</b> <b>3</b> 1 1 <b>3</b> <b>2</b> 1 <b>2</b> <b>3</b> <b>3</b> 1 <b>2</b> <b>2</b> <b>3</b> <b>3</b> 1 1 <b>2</b> <b>3</b> <b>2</b> 2 3They are then read out in rows: ...|$|R
5000|$|... 2, 1093, 11, 1093, <b>2,</b> 66161, 5, <b>3,</b> <b>2,</b> <b>3,</b> 71, 2693, <b>2,</b> 29, 29131, 1093, <b>2,</b> 5, <b>3,</b> 281, <b>2,</b> 13, 13, 5, <b>2,</b> <b>3,</b> 11, <b>3,</b> <b>2,</b> 7, 7, 5, <b>2,</b> 46145917691, <b>3,</b> 66161, <b>2,</b> 17, 8039, 11, <b>2,</b> 23, 5, <b>3,</b> <b>2,</b> <b>3,</b> ...|$|R
5000|$|... 0, 1, <b>2,</b> <b>3,</b> <b>2,</b> 5, <b>3,</b> 0, <b>2,</b> <b>3,</b> <b>2,</b> 0, <b>2,</b> <b>3,</b> 0, 0, <b>3,</b> 5, <b>2,</b> 0, 0, 7, 5, 0, 2, 7, 2, 0, <b>2,</b> 0, <b>3,</b> 0, 0, <b>3,</b> 0, 0, <b>2,</b> <b>3,</b> 0, 0, 6, 0, 3, 0, 0, 5, 5, 0, 3, <b>3,</b> 0, 0, <b>2,</b> 5, 0, 0, 0, <b>3,</b> <b>2,</b> 0, <b>2,</b> <b>3,</b> 0, 0, 0, 0, 2, 0, 0, 0, 7, 0, 5, 5, 0, ...|$|R
40|$|Contents Preface xiii I Background 1 1 Introduction <b>3</b> <b>2</b> ISO Standard Z 5 2. 1 History {{and current}} status 5 2. 1. 1 Z: {{the early years}} 5 2. 1. 2 The need for a change 6 <b>2.</b> 1. <b>3</b> Standardisation 7 <b>2.</b> 1. 4 Aims of this chapter 7 2. 2 Changed {{features}} of Standard Z 8 <b>2.</b> <b>3</b> Improvements 8 <b>2.</b> <b>3.</b> 1 Sections 8 <b>2.</b> <b>3.</b> <b>2</b> Mutually-recursive Free Types 9 <b>2.</b> <b>3.</b> <b>3</b> Operators 9 <b>2.</b> <b>3.</b> 4 Conjectures 9 <b>2.</b> <b>3.</b> 5 Binding Extensions and Tuple Selections 10 <b>2.</b> <b>3.</b> 6 Schemas as Expressions 11 <b>2.</b> <b>3.</b> 7 Empty Schemas 12 <b>2.</b> <b>3.</b> 8 Loose Generics 13 <b>2.</b> <b>3.</b> 9 Local Constant Declarations 13 <b>2.</b> <b>3.</b> 10 Axiom-parts as Predicates 14 <b>2.</b> <b>3.</b> 11 Soft Newlines 15 <b>2.</b> <b>3.</b> 12 Lexis of Words 15 <b>2.</b> <b>3.</b> 13 Toolkit 15 2. 4 Incompatibilities 16 2. 4. 1 Singleton Sets 16 ii Contents 2. 4. 2 Decorated References to Schemas 17 <b>2.</b> 4. <b>3</b> Decorated References to Generic Schemas 18 2. 4. 4 let on Predicates 18 2. 4. 5 Renaming on Theta Expressions 18 2. 4. 6 Underlined Infix Relations 19 2. 4. 7 Operator Precedences 19 2. 4. 8 Theta Expressions 21 2. 4. 9 Lexis of Words 21 2. 5 Subtle Changes 21 2. 5. 1 Qu...|$|R
40|$|The {{reaction}} of cobalt(II), nickel(II), copper(II) chlorides and bromides with thiophene- 3 -carboxaldoxime (3 TCOH) {{leads to a}} series of new complexes: [CoCl <b>2</b> (<b>3</b> TCOH) 4], [CoBr <b>2</b> (<b>3</b> TCOH) 4], [NiCl <b>2</b> (<b>3</b> TCOH) 4], [NiBr <b>2</b> (<b>3</b> TCOH) 4], [CuCl <b>2</b> (<b>3</b> TCOH) 4], [CuBr <b>2</b> (<b>3</b> TCOH) 2] respectively. The crystal structures of [CoBr <b>2</b> (<b>3</b> TCOH) 4], [NiBr <b>2</b> (<b>3</b> TCOH) 4] have been determined by X-ray diffraction methods showing octahedral complex species. In all complexes, the oxime functional group remains protonated and the coordination occurs through the nitrogen atom of the oxime moiety...|$|R
